Moeez ur Rehman’s Post

AstraZeneca’s CEO pay proposals for its 11 April 2024 AGM face a shareholder revolt after both ISS And Glass Lewis have recommended a vote against. But given the size and indusrty of AstraZeneca, and its use of, and exposure to the global talent market, particularly the USA the proposal seems to be preventative of trouble ahead, rather than curative of a current pay malaise within the current package. Much medical thinking likes preventative in preference to curative solutions, and so this approach seems reasonable, but the big question remains - is the quantum and mix proposal judged in the round a good move? And all this in the context of the LSE “Big Tent” discussion on UK competitiveness in many dimensions, including that of executive compensation levels and governance. NEWSPOINT takes a closer look… https://lnkd.in/e285CibR #executiveremuneration #LSE #astrazeneca #bigtent #corpgro #corporategrowth

AstraZeneca’s CEO pay proposals for its 11 April 2024 AGM face a shareholder revolt after both ISS And Glass Lewis have recommended a vote against. But given the size and indusrty of AstraZeneca, and its use of, and exposure to the global talent market, particularly the USA the proposal seems to be preventative of trouble ahead, rather than curative of a current pay malaise within the current package. Much medical thinking likes preventative in preference to curative solutions, and so this approach seems reasonable, but the big question remains - is the quantum and mix proposal judged in the round a good move? And all this in the context of the LSE “Big Tent” discussion on UK competitiveness in many dimensions, including that of executive compensation levels and governance. NEWSPOINT takes a closer look… https://lnkd.in/e285CibR #executiveremuneration #LSE #astrazeneca #bigtent #corpgro #corporategrowth

In light of the latest news, AstraZeneca's strategic move to boost drug stockpiles raison d'être is evident. Preparing for a potential no-deal Brexit, it amplifies an undercurrent whisper of uncertainty heard across Europe's marketplaces. Here's the significance of this decision unpacked: • **Judicious Preparedness:** A corporate behemoth like AstraZeneca leading the pack in preparing for an unsavory outcome—hard Brexit—crafts a layered fjord of precautionary preparedness. It is sparking others to reassess and revisit strategies, thus fostering an economic ecosystem bracing itself for turbulence. • **Trust Reinforcement:** Amid spikes in illicit pharmaceutical trade seizing the European Union, this move could shore up users' trust, asserting a robust buffer system's presence to circumvent disruptions. AstraZeneca's commitment to ensuring undisrupted access to medications proves valuable for public faith resurgence. Now, what does the future hold? • **Innovation imperative:** A call to arms for cross-sector innovation is increasingly felt. The counterfeit medicine plague incentivizes a rethink in strategy, unearthing new opportunities for businesses demonstrating ability to pivot, innovate, and adapt. • **Consumer-centric evolution:** The companies critical to public health, such as AstraZeneca, are expected to lead a consumer-centric transition–paving the way to respond proactively to future uncertainties. Life sciences is an arena known for resilience, yet the testing contours of hard Brexit may immeasurably amplify this testimony. Moving next, it’s interesting to observe how businesses reshape their roadmaps to remain buoyant in face of imminent adversities and circumvent risks more astutely. Keep a pulse on what the ramifications of Brexit mean for EU's Life Sciences and Health sector [here](https://lnkd.in/d9tzpiqs). #healthcare #lifesciences #brexit #uncertainty #preparedness #innovation #trust #publichealth #businessstrategy

Michel Demaré, Chair of the Board at AstraZeneca Plc, and Chairman of the Foundation and Supervisory Boards at IMD, presented at the launch of our Role of the Chair session IMD. With his experience in 9 industries across 4 continents, Mr. Demaré’s view on the role of the chair is crystallised: “Attitude is the most important trait for this role - there's no room for egos. The CEO is the window of the company, and it’s my role to ensure he/she is successful. I consider myself a mentor, offering guidance, bouncing ideas, and providing support.” He emphasises that Emotional Intelligence (EQ) is more important than IQ for being a chair. “It is about empathy, listening to people, focusing on detecting and developing talents, and managing relationships with all stakeholders.” Regarding CEO succession, Mr. Demaré mentioned that it involves regular evaluations and transparent discussions, benchmarking candidates on attitude, personality, and management style to ensure readiness for future challenges. It is essential to fully involve the CEO in the process. As a chair, he meets the candidates on a regular basis and socialises to get to know them better. An important part of his job is to engage, not only with the executives, but with as many employees as possible to explain to them the role of the board and understand diverse perspectives. As the chair of one of the largest pharmaceutical companies in the world, the company is dedicated to going beyond business – e.g. initiatives for improving the resilience of health systems and fostering public-private partnerships. Nonetheless, while long-term strategic thinking is crucial in healthcare, the fast pace of change in science and business forces boards to also focus on shorter-term milestones. What is important is to get the right balance between long-term and short-term strategy.” 💡 These are key takeaways from the session 💡: -         Governance and Strategy: To understand the role of the chair, it is a prerequisite to understand the role of the board. It’s all about governance, strategy and people. Ensuring an understanding of governance is essential. Promoting a positive culture and ensuring a cooperative, respectful environment is also crucial. -         Managing Chair-CEO Relationships: The relationship between the CEO and the Chair is key. This is not a competition, but a constructive, yet challenging relationship. The chair’s ultimate satisfaction is to see the CEO shine. Regular engagement with the CEO, and building a relationship based on mutual respect and trust are essential for organisational success. In the complex and fast-paced business environment today, it is imperative to explore the right role of the chair for effective governance of organisations. Learn more about the program here: https://bit.ly/3wNIVTB, and about the Board & Governance programs here: https://bit.ly/3R95dG3 #IMDImpact #IMDBoardCenter #HighPerformanceBoards #CorporateGovernance #BoardofDirectors #BoardChair

GSK rewards CEO Emma Walmsley with 51% pay hike after beating sales, profit goals With the fortunes of GSK on the rise after much tumult early in the decade, the company has rewarded CEO Emma Walmsley with a significant pay boost. Walmsley collected 12.7 million pounds sterling ($16 million) in total pay last year, a 51% increase from her compensation in 2022. GSK revealed (PDF) the latest pay figure in its corporate governance annual report. It’s a long way from 2021 when Elliott Management was pushing to replace Walmsley, followed by Bluebell Capital Partners, which asked GSK’s board to look for new leadership and require Walmsley to reapply for her job. Since then, however, Walmsley has executed a spinoff of GSK’s consumer health unit and put the company back on course for growth. In 2023, GSK's global revenue increased by 5%. Excluding sales of COVID products, GSK’s sales were up by 14%. In addition, the company’s share price rose by 11% in 2023 and is up 14% so far this year. After striking out in its attempts to develop a COVID shot, the U.K.-based company has reestablished itself as a vaccine powerhouse. Last year, GSK became the first company to score FDA approval for a respiratory syncytial virus vaccine. Its first-to-the-market status with Arexvy helped pave the way for sales of 1.2 billion pounds ($1.5 billion) during its first several months on the market. https://lnkd.in/exENKDds

📈 Abbott (ABT) Outperforms Market Expectations! 🌟 Great news for investors and stakeholders! Abbott (ABT) has exceeded market returns, showcasing its resilience and robust performance in the healthcare sector. 🌐 Key Highlights: -Abbott's strategic initiatives and innovative product launches have driven this impressive growth. -Consistent focus on expanding their medical device and diagnostics portfolios has paid off significantly. -The company's strong financial performance is a testament to its commitment to improving global health. -This achievement underscores Abbott's position as a leader in the healthcare industry, continuously delivering value to its shareholders and making impactful contributions to medical advancements. 🚀 Let's celebrate this milestone and look forward to more groundbreaking achievements from Abbott! #Abbott #MarketPerformance #HealthcareInnovation #InvestmentSuccess #MedicalDevices #Diagnostics #GlobalHealth #FinancialGrowth #StockMarket #InvestorNews

As India marks its 78th year of independence, we at AstraZeneca draw inspiration from the nation's unwavering spirit of progress and resilience. We are dedicated to contributing to a healthier, independent India, ensuring that every citizen has access to world-class healthcare. By merging cutting-edge science, advanced data analytics, and innovative technologies, we are at the forefront of medical advancement. Our patient-centric approach ensures that every decision is guided by their needs, enabling them to live fuller lives. With a 45-year legacy of transforming healthcare, AstraZeneca India continues to focus on developing groundbreaking treatments aimed at improving patient outcomes, optimising healthcare systems, and protecting the environment. Together, let's build a healthier, more resilient India with AstraZeneca's commitment to science-based innovation and patient well-being. #IndependenceDay #15August #78IndependenceDay

The trend towards 'regionalized' supply chains is reflected in the description here by AstraZeneca's CEO Pascal Soriot of a 'two supply chain' strategy; one for the 'east' and one for the 'west'. Almost every company is grappling with the implications of the escalating US-China trade war yet it is a different calculus when China is a large and growing market as well as a manufacturing base. Pascal also notes that R&D will continue to be a global function so that innovations in any market can be leveraged by any other market. A great 'companion piece' to this is the recent and engaging discussion between Gartner's Thomas O'Connor and AZ's Matt Winterman ('How AstraZeneca Adapts Strategic Decision Making for Resilience': https://lnkd.in/eSPYzhWa) in which they discuss: - The fundamentals of strategic decision making for AstraZeneca. - How AstraZeneca adapts its supply chain to drive both cost optimization and business growth. - The role that 'timing' plays in making investments in new capabilities. - Methods to encourage talent to join change management journeys. - How supply chain leaders can understand their organization’s underpinnings for decision making. I would also recommend this great discussion between AZ's Lucy Alexander and Richard Bendis (https://lnkd.in/eDG9k42R) in which she provides a great explanation of the many different dynamics that AZ has to balance and react to (including sustainability) and the role of digitization in evolving planning and execution processes. #supplychain #supplychainmanagement #supplychainresilience #supplychainrisk Adebayo Adeleke Alan Amling Benjamin Gordon Daniel Stanton Gary S. Lynch Jason Miller Joe Carson Sunita Suryanarayan Jon W. Hansen Knut Alicke Marc Dragon Radu Palamariu Rob Handfield Sheri R. Hinish Stan Aronow Tom Raftery Wolfgang Lehmacher Margi Van Gogh Ted Stank Kathy Fulton Niall Murphy Rushit Shah Ryan Elliott William O'Donnell Eric Topp John McFall BSc MBA FCMI Ross Valentine Steven Daugherty Joanne Joliet Lindsay Azim Joanne Spencer Heather Wheatley Lauren Wheatley Sarah Watt

Alliance Pharma COO to quit company after less than two years 💊🤔 Chippenham-based Alliance Pharma, which posted revenues of £187 million for the year ended 31 December 2023 – up 8 per cent on 2022, has announced that Jeyan Heper, its Chief Operating Officer, will leave the business a the end of August. Jeyan Heper joined Alliance as COO and Board member on 1 February 2023, helping to identify growth opportunities in international consumer healthcare markets and supporting the Board and senior executive team to develop the strategy for international markets, particularly China and the US. Butt the Board has decided that the role of COO is no longer a requirement at Alliance, citing a simplification of the company's management structure, acceleration of a globalisation of the business and to bring the consumer closer to the heart of the business as reasons. Nick Sedgwick, Chief Executive Officer of Alliance, said... Continue reading... https://lnkd.in/dFZARUn6 #pharmaceuticals #medical #health #careers #jobs #recruitment #executive #leadership #businessnews #businessintelligence

Covid put supply chains in the mainstream consciousness. Subsequent disruptions, shocks, and emerging risks only increase the trend toward de-risking, which often involves moving away from single suppliers and reliance on only the furthest flung sources of inventory. What does this mean for the logistics industry? Customers typically use different providers for domestic, regional, and global logistics, but now the desire is to merge the three into a single intermixed flow of goods. This being resilience and flexibility. But the challenge is almost no provider can manage all of these as one today. Those who can charge a 4PL/3PL+ premium only the biggest players can justify. But tech platforms and demand will bring the tools and processes needed increasingly into the hands of medium-sized players too. This is the biggest strategic shift in logistics since globalisation took off, and the many factors driving it are only getting more severe. Change is afoot. #shipping #design #strategy #maersk #logistics #economics